While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.
Yale Cancer Center | Strategic Alliance Partners
Latest from Yale Cancer Center
Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.
Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.
Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer
Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.
Dr. Roy S. Herbst from Yale Comprehensive Cancer Center on Themes From the 2011 Lung Cancer Congress
Dr. Roy S. Herbst from Yale comprehensive cancer center on the International Lung Cancer Congress
Dr. Roy Herbst from the Yale Comprehensive Cancer Center on Screening Studies at the Upcoming Lung Cancer Congress
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Surgeons, Medical Oncologists, and Radiation Oncologists Debate Current Thresholds for Systemic Therapy in EGFR-Mutated NSCLC
5